Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 05 Sep 2019
What is the value of market-wide health care price transparency?
5 September 2019 - A primary driver of high spending in the US health care system, relative to other countries, ...
Posted by Michael Wonder on 15 Aug 2019
ICER's value framework and patient feedback: Q&A with Steve Pearson
15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...
Posted by Michael Wonder on 14 Aug 2019
Costing methods applied to cancer
8 August 2019 - Health care is vital in improving quality and length of life. ...
Posted by Michael Wonder on 27 Jul 2019
A non-inferiority framework for cost-effectiveness analysis
24 July 2019 - Traditional decision rules have limitations when a new technology is less effective and less costly than a ...
Posted by Michael Wonder on 22 Jul 2019
Should national pharmacare apply a value based insurance design?
22 July 2019 - The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, ...
Posted by Michael Wonder on 16 Jul 2019
Ask whether a drug works before worrying about what it costs
16 July 2019 - Last week was supposed to be a turning point for drug price transparency. ...
Posted by Michael Wonder on 25 Jun 2019
Do cancer treatments have option value? Real‐world evidence from metastatic melanoma
24 June 2019 - A change in the expectations about future treatments may change the option value of a current ...
Posted by Michael Wonder on 24 Jun 2019
It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach
24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...
Posted by Michael Wonder on 20 Jun 2019
Novel approaches to value assessment within the cost-effectiveness framework
20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...
Posted by Michael Wonder on 20 Jun 2019
Drug pricing should reflect value, not recoupment of investment
20 June 2019 - The other day I was reading a piece on reframing the conversation on drug pricing. I ...
Posted by Michael Wonder on 18 Jun 2019
Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price
18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...
Posted by Michael Wonder on 15 Jun 2019
New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?
12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...
Posted by Michael Wonder on 11 Jun 2019
Systematic literature review calls economic impact of switching to biosimilars "uncertain"
10 June 2019 - Biosimilar drugs are intended by their developers to provide a cost-saving alternative to brand-name biologics, and ...